US4622221004
© BusinessWire
12.01.2026
IONS
LISTED
NASDAQ
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 8:15am PT; the presentation is available today on the Ioni...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
IONS
LISTED
NASDAQ
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). The studies included over 1,800 patients from 29 coun...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
IONS
LISTED
NASDAQ
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026.
A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis web...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
02.12.2025
IONS
LISTED
NASDAQ
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological condition. Over time, it can lead to loss of mobility and independence, along with dif...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
01.12.2025
IONS
LISTED
NASDAQ
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). Breakthrough Therapy designation is...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
IONS
LISTED
NASDAQ
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults a...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
IONS
LISTED
NASDAQ
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
News Preview
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
IONS
LISTED
NASDAQ
Ionis to present at upcoming investor conferences
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Stifel 2025 Healthcare Conference on Thursday, November 13, 2025
Jefferies Global Healthcare Conference on Tuesday, November 18, 2025
A live webcast of these presentations can be accessed on...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
IONS
LISTED
NASDAQ
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
News Preview
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
IONS
LISTED
NASDAQ
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) le...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
IONS
LISTED
NASDAQ
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA™ (donidalorsen), the first and only RNA-targeted prophylactic medicine for hereditary angioedema (HAE), to be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida. Results demonstrat...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
IONS
LISTED
NASDAQ
Ionis reports third quarter 2025 financial results and highlights progress on key programs
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2025.
"The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more antic...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.10.2025
IONS
LISTED
NASDAQ
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during a late-breaking session, titled “Groundbreaking Trials in Cardiometabolic Therapeutics”, at the American Heart Association (AH...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
IONS
LISTED
NASDAQ
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based on industry-leading innovation, strong alignment of compa...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
IONS
LISTED
NASDAQ
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis’ chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS), a nonprofit organization that fosters academia and industry-based research and development of oligonucleotide therapeutics. The O...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
IONS
LISTED
NASDAQ
Ionis to hold third quarter 2025 financial results webcast
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results and progress on key programs.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be availabl...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
IONS
LISTED
NASDAQ
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company’s recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
IONS
LISTED
NASDAQ
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
IONS
LISTED
NASDAQ
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products f...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2025
IONS
LISTED
NASDAQ
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA) access to adaptive surfing, the event has expanded to include a myriad of adaptive experiences and will we...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
IONS
LISTED
NASDAQ
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication,...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
IONS
LISTED
NASDAQ
Ionis to host investors and analysts for Innovation Day 2025
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York.
The agenda will feature presentations from members of the Ionis leadership team as well as a key thought leader in the treatment of severe hypertriglyceridemia, familial chylomicronemia syndrome and lipid di...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
IONS
LISTED
NASDAQ
Ionis to present at upcoming investor conferences
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025
H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025
Morgan Stanley 23rd Annual Global H...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
IONS
LISTED
NASDAQ
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In the studies, olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a hig...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
IONS
LISTED
NASDAQ
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designe...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
IONS
LISTED
NASDAQ
Ionis reports second quarter 2025 financial results and highlights progress on key programs
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.
“During the second quarter, we continued to build momentum across our business,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our strong performance included excellent...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
IONS
LISTED
NASDAQ
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
IONS
LISTED
NASDAQ
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were published in The Journal of Allergy and Clinical Immunology (JACI) In Practice. Results indicate that patients who switched to donidalorsen from prior...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
IONS
LISTED
NASDAQ
Ionis to hold second quarter 2025 financial results webcast
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on key programs.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
IONS
LISTED
NASDAQ
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINR...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
IONS
LISTED
NASDAQ
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role.
“Richard has made tremendous contributions to Ionis over his...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
IONS
LISTED
NASDAQ
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that lea...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
IONS
LISTED
NASDAQ
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk for atherosclerotic cardiovascular disease (ASCVD). Nearly all the participants were on current standard of care lip...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
IONS
LISTED
NASDAQ
Ionis to host 2025 virtual Annual Meeting of Stockholders
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025.
The agenda for the event is as follows:
5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders
All stock...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
IONS
LISTED
NASDAQ
Ionis reports first quarter 2025 financial results
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the first quarter ended March 31, 2025.
“With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis’ new chapter as a fully integrated, commerc...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
IONS
LISTED
NASDAQ
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven’t yet found the best treatment option for them. The Ionis-sponsored survey was condu...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
IONS
LISTED
NASDAQ
Ionis to hold first quarter 2025 financial results webcast
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
IONS
LISTED
NASDAQ
Ionis to host expert panel discussion on sHTG
News Preview
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., se...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
IONS
LISTED
NASDAQ
Ionis to present at upcoming investor conferences
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025
Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025
2025 RBC Capital Markets Global Healthcare Confe...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
IONS
LISTED
NASDAQ
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a potential treatment for familial chylomicronemia syndrome (FCS) and severely elevated triglycerides. Ionis will continue...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
IONS
LISTED
NASDAQ
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potenti...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
IONS
LISTED
NASDAQ
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only app...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
IONS
LISTED
NASDAQ
Ionis to present at upcoming investor conferences
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025
TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025
Leerink Partners Global Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
IONS
LISTED
NASDAQ
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company’s investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
IONS
LISTED
NASDAQ
Ionis reports fourth quarter and full year 2024 financial results
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024.
“With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology com...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
IONS
LISTED
NASDAQ
Ionis to hold fourth quarter and full year 2024 financial results webcast
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limit...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
IONS
LISTED
NASDAQ
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
News Preview
– Accelerating value creation with numerous commercial, regulatory and pipeline milestones –
– Ionis outlines clear path to sustained positive cash flow –
CARLSBAD, Calif., Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones exp...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IONS
LISTED
NASDAQ
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
CARLSBAD, Calif., Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Wednesday, January 15, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
IONS
LISTED
NASDAQ
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
News Preview
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis TRYNGOLZA is the first of four independent launches planned over the next t...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
IONS
LISTED
NASDAQ
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
News Preview
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 designBayley-4 expressive communication selected as Phase 3 study primary endpointInitiation of ION582 Phase 3 study planned for H1 2025Ionis to share ION582 program update at the FAST Global Science Summit in NovemberCARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis P...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
IONS
LISTED
NASDAQ
Ionis reports third quarter 2024 financial results
News Preview
WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion
Olezarsen FCS PDUFA December 19, 2024
Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process
On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance
CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
IONS
LISTED
NASDAQ
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
News Preview
Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approvalDonidalorsen PDUFA date set for August 21, 2025Donidalorsen has the potential to be Ionis' second independent commercial launchCARLSBAD, Calif., Nov. 4, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U....
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
IONS
LISTED
NASDAQ
Ionis to hold third quarter 2024 financial results webcast
News Preview
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results....
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2024
IONS
LISTED
NASDAQ
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
News Preview
- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo
CARLSBAD, Calif., Oct. 21, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen)...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
IONS
LISTED
NASDAQ
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
News Preview
– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing
CARLSBAD, Calif., Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-la...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
IONS
LISTED
NASDAQ
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
News Preview
Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological conditionCARLSBAD, Calif., Oct. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
IONS
LISTED
NASDAQ
Ionis announces pricing of $500.3 million public offering
News Preview
CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are e...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2024
IONS
LISTED
NASDAQ
Ionis announces proposed public offering of common stock
News Preview
CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
IONS
LISTED
NASDAQ
Ionis to present at upcoming investor conferences
News Preview
CARLSBAD, Calif., Aug. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
2024 Wells Fargo Healthcare Confer...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
